Alterome Therapeutics, Inc.
San Diego, US · Founded 2021 · Delaware corporation · 5 known investors
Alterome develops targeted, genomically-defined cancer therapies aimed at aggressive cancers that lack effective treatment options, focusing on more precise drugs with fewer off-target effects. It serves cancer patients by targeting disease-driving genetic alterations.
BiotechHealthtechMedical Devices
Founders & leadership
Alterome Therapeutics, Inc. was founded in 2021 by Eric A. Murphy.
EA
Eric A. MurphyFounder
RB
Ryan B. CorcoranNamed on SEC filing
Board
CG
AG
Investors · 5
Reported raises · per SEC filings
Form D private placements$63.8M disclosed across 1 round · 2021
▶$63.8MraisedJan 2022 · 9 investors · BiotechnologyRule 506(b)
▶$63.8MraisedJan 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric A. MurphyExecutive Officer, Director, Promoter
- Thilo SchroederDirector
- Ryan B. CorcoranDirector, Promoter
- Carl GordonDirector
- Arjun GoyalDirector
- Offering amount
- $63.8M
- Amount sold
- $63.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapImmunome50 shared keywordsImmunome is a clinical-stage oncology company that discovers and develops targeted cancer therapies, with a focus on antibody-drug conjugates (ADCs). Its pipeline includes varegacestat (a gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1-targeted ADC), and IM-3050 (a FAP-targeted radioligand), aimed at addressing high unmet need in cancer treatment.
Noveome Biotherapeutics40 shared keywordsNoveome is a biopharmaceutical company developing ST266, a multi-targeted secretome biologic containing biologically active proteins and factors aimed at neuroprotection, inflammation modulation, and cell recovery. The company is targeting underserved conditions in ophthalmology, neurology, and dermatology.
Nucleome32 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Cellanome31 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
nChroma Bio26 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Freenome21 shared keywordsFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
Companies competing with Alterome Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Alterome Therapeutics, Inc. do?
- Alterome develops targeted, genomically-defined cancer therapies aimed at aggressive cancers that lack effective treatment options, focusing on more precise drugs with fewer off-target effects. It serves cancer patients by targeting disease-driving genetic alterations.
- Who founded Alterome Therapeutics, Inc.?
- Alterome Therapeutics, Inc. was founded by Eric A. Murphy in 2021.
- Who are Alterome Therapeutics, Inc.'s investors?
- Alterome Therapeutics, Inc.'s investors include Canaan Partners, Nextech Invest, OrbiMed, Vida Ventures, Digitalis Ventures.
- How much funding has Alterome Therapeutics, Inc. raised?
- Alterome Therapeutics, Inc. has disclosed $63.8M raised across 1 round.
- Where is Alterome Therapeutics, Inc. headquartered?
- Alterome Therapeutics, Inc. is headquartered in San Diego, US.